JP2018522891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522891A5 JP2018522891A5 JP2018503215A JP2018503215A JP2018522891A5 JP 2018522891 A5 JP2018522891 A5 JP 2018522891A5 JP 2018503215 A JP2018503215 A JP 2018503215A JP 2018503215 A JP2018503215 A JP 2018503215A JP 2018522891 A5 JP2018522891 A5 JP 2018522891A5
- Authority
- JP
- Japan
- Prior art keywords
- brain injury
- traumatic brain
- pharmaceutical composition
- peptides
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 19
- 230000009529 traumatic brain injury Effects 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 8
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims 6
- 208000029028 brain injury Diseases 0.000 claims 6
- 210000004556 brain Anatomy 0.000 claims 4
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 claims 3
- 108700028369 Alleles Proteins 0.000 claims 2
- 108010060215 Apolipoprotein E3 Proteins 0.000 claims 2
- 102000008128 Apolipoprotein E3 Human genes 0.000 claims 2
- 208000007333 Brain Concussion Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 102000003802 alpha-Synuclein Human genes 0.000 claims 2
- 108090000185 alpha-Synuclein Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 108010071619 Apolipoproteins Proteins 0.000 claims 1
- 102000007592 Apolipoproteins Human genes 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022079211A JP2022113682A (ja) | 2015-07-21 | 2022-05-13 | 凝集ペプチドを標的とする外傷性脳損傷の治療方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195183P | 2015-07-21 | 2015-07-21 | |
| US62/195,183 | 2015-07-21 | ||
| US201662288813P | 2016-01-29 | 2016-01-29 | |
| US62/288,813 | 2016-01-29 | ||
| PCT/IB2016/054318 WO2017013599A1 (en) | 2015-07-21 | 2016-07-20 | Method for treatment of traumatic brain injury targeting aggregated peptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022079211A Division JP2022113682A (ja) | 2015-07-21 | 2022-05-13 | 凝集ペプチドを標的とする外傷性脳損傷の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522891A JP2018522891A (ja) | 2018-08-16 |
| JP2018522891A5 true JP2018522891A5 (enExample) | 2019-08-15 |
Family
ID=56550266
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018503215A Pending JP2018522891A (ja) | 2015-07-21 | 2016-07-20 | 凝集ペプチドを標的とする外傷性脳損傷の治療方法 |
| JP2022079211A Pending JP2022113682A (ja) | 2015-07-21 | 2022-05-13 | 凝集ペプチドを標的とする外傷性脳損傷の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022079211A Pending JP2022113682A (ja) | 2015-07-21 | 2022-05-13 | 凝集ペプチドを標的とする外傷性脳損傷の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11327080B2 (enExample) |
| EP (1) | EP3325506A1 (enExample) |
| JP (2) | JP2018522891A (enExample) |
| CN (1) | CN107849125A (enExample) |
| AU (1) | AU2016295650A1 (enExample) |
| CA (1) | CA2991856A1 (enExample) |
| WO (1) | WO2017013599A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6674888B2 (ja) | 2013-03-13 | 2020-04-01 | プロセナ バイオサイエンシーズ リミテッド | タウ免疫療法 |
| PL3452507T3 (pl) | 2016-05-02 | 2023-01-09 | Prothena Biosciences Limited | Immunoterapia tau |
| CN109219615B (zh) | 2016-05-02 | 2022-12-09 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| CN110881274B (zh) | 2017-05-02 | 2024-11-15 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| AU2020231366A1 (en) | 2019-03-03 | 2021-08-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100767146B1 (ko) | 2000-02-24 | 2007-10-15 | 워싱톤 유니버시티 | Ａβ 펩티드를 격리시키는 인간화 항체 |
| AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| WO2006069081A2 (en) * | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY |
| BRPI0709050B1 (pt) * | 2006-03-23 | 2018-12-26 | Bioarctic Neuroscience Ab | anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| PT2448968T (pt) | 2009-06-29 | 2021-04-30 | Bioarctic Ab | ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL |
| WO2011026031A1 (en) | 2009-08-28 | 2011-03-03 | The Board Of Regents Of The University Of Texas System | Antibodies that bind tau oligomers |
| US10266585B2 (en) | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| AR083819A1 (es) * | 2010-11-10 | 2013-03-27 | Genentech Inc | UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL |
| WO2013168174A1 (en) * | 2012-05-08 | 2013-11-14 | Ramot At Tel-Aviv University Ltd. | Apoe4 antibodies for treatment of neurodegenerative conditions |
| HK1215673A1 (zh) * | 2012-12-07 | 2016-09-09 | Biogen International Neuroscience Gmbh | 一個使用抗ab抗體減少腦部澱粉蛋白質斑的方法 |
| US20160355573A1 (en) | 2013-09-05 | 2016-12-08 | Cornell University | Gene therapy for alzheimer's and other neurodegenerative diseases and conditions |
| US20150126390A1 (en) * | 2013-09-12 | 2015-05-07 | Washington University | Multiplex avidity profiling of protein aggregates |
| SI3166970T1 (sl) * | 2014-07-10 | 2021-09-30 | Bioarctic Ab | Izboljšana A-beta protofibril vezavna protitelesa |
-
2016
- 2016-07-20 US US15/746,283 patent/US11327080B2/en active Active
- 2016-07-20 AU AU2016295650A patent/AU2016295650A1/en not_active Abandoned
- 2016-07-20 CN CN201680042690.4A patent/CN107849125A/zh active Pending
- 2016-07-20 EP EP16742413.4A patent/EP3325506A1/en not_active Ceased
- 2016-07-20 WO PCT/IB2016/054318 patent/WO2017013599A1/en not_active Ceased
- 2016-07-20 JP JP2018503215A patent/JP2018522891A/ja active Pending
- 2016-07-20 CA CA2991856A patent/CA2991856A1/en not_active Abandoned
-
2022
- 2022-05-13 JP JP2022079211A patent/JP2022113682A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522891A5 (enExample) | ||
| Jin et al. | Minocycline improves postoperative cognitive impairment in aged mice by inhibiting astrocytic activation | |
| FI3562486T3 (fi) | Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa | |
| JP2014530226A5 (enExample) | ||
| BR112016020919A2 (pt) | redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc | |
| WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
| WO2016210372A3 (en) | Methods to treat neurological diseases | |
| Schmitt et al. | Role of HDACs in optic nerve damage-induced nuclear atrophy of retinal ganglion cells | |
| WO2014144130A3 (en) | Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof | |
| JP2014518275A5 (enExample) | ||
| Lee et al. | Effect of a selective mas receptor agonist in cerebral ischemia in vitro and in vivo | |
| JP2016512817A5 (enExample) | ||
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| Alme et al. | Fingolimod does not enhance cerebellar remyelination in the cuprizone model | |
| JP2016507547A5 (enExample) | ||
| RU2010142456A (ru) | Синергические комбинации 5'-метилтиоаденозина | |
| Makino et al. | Enhancement of immobility in mouse forced swimming test by treatment with human interferon | |
| Kan et al. | Matrine protects neuro-axon from CNS inflammation-induced injury | |
| JP2019528285A5 (enExample) | ||
| ATE482711T1 (de) | Kombinationsprodukt mit einem antagonisten oder inversen agonisten von histamine-rezeptor h3 und einem antipsychotischen oder antidepressiven mittel, und ihre verwendung zur herstellung eines medikaments zur verhinderung der nachteiligen wirkungen von psychotropika | |
| Johnson‐Ansah et al. | Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia | |
| BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
| WO2023245156A3 (en) | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | |
| BRPI1008103A2 (pt) | " peptídeo de cadeia curta isolado, composição farmacêutica, compostos, método de evitar ou tratar doenças, medicamento para tratar/ reduzir condições médicas e uso dos compostos " | |
| JP2017537083A5 (enExample) |